Theo Leitner

Ratzeburger Allee 160
Luebeck, SH 23538, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Journal: Leukemia & lymphoma

Published: July 28, 2026

FASTINA - protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy.

FASTINA - protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy.

Journal: Pilot and feasibility studies

Published: February 02, 2026

Health-related quality of life after autologous stem cell transplantation for multiple myeloma or lymphoma impacts professional activity- an analysis from two German tertiary care centers.

Health-related quality of life after autologous stem cell transplantation for multiple myeloma or lymphoma impacts professional activity- an analysis from two German tertiary care centers.

Journal: Frontiers in oncology

Published: January 01, 2026

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Journal: American journal of hematology

Published: December 02, 2025

Survival in patients with monoclonal gammopathy of unknown significance after transcatheter aortic valve replacement: a global retrospective propensity-matched real-world analysis.

Survival in patients with monoclonal gammopathy of unknown significance after transcatheter aortic valve replacement: a global retrospective propensity-matched real-world analysis.

Journal: Cardio-oncology (London, England)

Published: November 24, 2025

Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis.

Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 02, 2025

AI-based body composition analysis of CT data has the potential to predict disease course in patients with multiple myeloma.

AI-based body composition analysis of CT data has the potential to predict disease course in patients with multiple myeloma.

Journal: Scientific reports

Published: February 10, 2025

Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.

Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.

Journal: International journal of molecular sciences

Published: October 31, 2024

A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma.

A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma.

Journal: HemaSphere

Published: October 01, 2024

Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample.

Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample.

Journal: Haematologica

Published: April 11, 2024

Real-world analysis of teclistamab in 123 RRMM patients from Germany.

Real-world analysis of teclistamab in 123 RRMM patients from Germany.

Journal: Leukemia

Published: November 10, 2023

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.

Journal: Blood

Published: February 07, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026